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This research provides ultrastructural information 
regarding pulmonary surfactant secretion from stimulation of 
adrenergic pathways to the lung via the stellate ganglion. 
This information will help clarify the important role of the 
sympathetic nervous system in surfactant disorders. It also 
provides insight into sympathetic mechanisms causing 
surfactant derangement in adult and infant respiratory 
distress syndromes (RDS). Basic cellular mechanisms of 
surfactant metabolism, including synthesis and packaging in 
lamellar bodies, were studied. Results shed light on these 
basic processes of lung cell function. 
The results of this study provide new avenues for 
studying a problem in health care that has long resisted 
advances, that of surfactant replacement therapy. It is 
expected that the results of this research, taken with 
information from other researchers, will ultimately reduce 
the 50% mortality rate of the 150,000 patients annually 
suffering from RDS (Andreadis and Petty 1985). 
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Discovery of Surfactant 
The concept of a surface active material in the lungs 
has interested physiologists for over 40 years. In 1929, 
von Neergaard demonstrated the effects of surface forces on 
the pressure-volume characteristics of excised lungs and 
speculated that the surface tension of alveolar fluid might 
be decreased to below that commonly found for other 
biological fluids (von Neergaard 1929). Although many have 
since repeated von Neergaard's simple experiment, the 
magnitude of this effect was not fully appreciated for three 
decades. Pattle (1958) and Clements and co-workers (1958) 
showed that alveolar lung fluid forms an insoluble film at 
an air-liquid interface and modifies the surface tension of 
this interface in a manner which depends on alveolar surface 
area. Recently it has been advocated that surfactant should 
be considered to act not only as a detergent role by 
locating at air-aqueous interfaces and reducing surface 
tensions, but in modifying solid surfaces to which it is 
absorbed (Hills and Bryan-Brown 1983). 
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Alveolar Type II Cells 
The synthesis and secretion of pulmonary surfactant is 
initiated in fetal lung tissue during the latter stages of 
gestation (Comroe 1974). As the type II cell differentiates 
in late gestation, cell size decreases, glycogen is greatly 
depleted, and lamellar bodies, the hallmark of the type II 
cell, appear in the cytoplasm (Williams and Mason 1977). 
Vidic and Burri (1981) showed in a study using the rat type 
II pneumonocyte that not only subcellular components but the 
type II cell as a whole undergoes quantitative changes in 
early postnatal life. 
Alveolar type II cells are usually situated in the 
alveolar niche between capillaries. The cells are roughly 
cuboidal in shape and provided with irregular short 
microvilli on their free surface. The cells are tightly 
attached to the adjacent squamous epithelial cells. The 
most striking feature of these cells is the presence of 
characteristic lamellar inclusion bodies. The lamellar 
bodies store surfactant and secrete their content into the 
alveolar lumen by an exocytosis process, stimulated by 
alveolar expansion, beta adrenergic mechanisms (Bourbon and 
Rieutort 1987) and with possible involvement of microtubules 
(Stratton 1976). 
Once outside the cell, lamellar bodies unfold to form 
tubular myelin, a unique physical form of surface active 
material that on cross-section appears as a lattice formed 
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from adjoined rectangular tubes. It is generally considered 
as a transition form between packaged surfactant and the 
functional monolayer lining, which subsequently spreads over 
the alveolar surface. Tubular myelin contains lipids 
similar to those in surface active material, and Gil and 
Reiss (1973) have suggested that calcium is involved in its 
formation. Finally, tubular myelin is adsorbed to the air-
liquid interface to form the surface film. 
The main functions of type II cells are synthesis and 
secretion of pulmonary surface active material. A second 
major function of type II cells is to regenerate a 
continuous epithelium after diffuse alveolar injury. Type 
II cells may secrete substances other than surface active 
material, such as enzymes, but the functions of these 
enzymes are not known (Mason et al. 1977). A final 
postulated function of the type II cells is control of the 
electrolyte composition of the alveolar subphase, a very 
thin aqueous layer between alveolar epithelial cells and the 
air-liquid interface. Mason and Williams (1977) were the 
first to directly demonstrate fluid and electrolyte 
transport by alveolar epithelial cells, concluding that 
alveolar epithelial cells .have the ability to transport 
fluid from the alveolar subphase into the interstitium. 
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Surface Tension 
References to alveolar surface tension are common in 
the physiological and clinical literature today, and most 
investigators are willing to accept the validity of a 
specialized material called pulmonary surfactant. Most 
agree that pulmonary surfactant phospholipid is synthesized 
in, stored in, and released from alveolar type II cells 
(Dobbs and Mason 1979). After birth, the secreted 
surfactant lines the alveolus and reduces surface tension at 
the air-liquid interface. 
Surface tension is a manifestation of attracting forces 
between atoms or molecules. Surface tension has the units 
of force per unit of length, and the units of surface 
tension are dynes per centimeter. At 37 degrees centigrade, 
pure water has a surface tension of 70 dynes per centimeter; 
blood plasma and most tissue fluids at equilibrium have a 
surface tension of 50 dynes per centimeter (Comroe 1974). 
Assuming that the alveolar film exerts a surface 
tension of 50 dynes per centimeter, calculations would 
indicate that the surface tension recoil of the lung would 
be 20,000 dynes per square centimeter and would exert a 
pressure of about 20 centimeters water. This calculated 
value is five to ten times too large at usual or low lung 
volumes. The surface tension of the alveolar film at small 
lung volumes must then be five to ten dynes per centimeter 
instead of 50 dynes per centimeter. This lead Clements 
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(1958) to suspect that the surface tension in the lung fluid 
is high when the lungs are inflated and very low when they 
are deflated. This could occur only if the alveolar lining 
were something other than saline or ordinary tissue fluid; 
it must contain a special type of surface active material. 
Several early experimental observations influenced the 
methodology that has been used to purify surfactant. 
Clements (1958) obtained materials from the lungs by 
repeated rinsing of the airways and airspaces to study this 
surface active material, or surfactant. The surface was 
compressed to mimic compression of the alveolar - lining 
during expiration, and then expanded, to mimic its expansion 
during inspiration. The results were remarkable. The 
surface tension rose to 40-50 dynes per centimeter when the 
film was expanded, and dropped nearly to zero when the film 
was compressed. 
An alveolus with a low surface tension requires a low 
air pressure to maintain a given radius or volume; one with 
a high surface tension requires a large counter-pressure. 
Low surface tension, therefore, reduces the muscular effort 
necessary to ventilate the lungs and keep them aerated. 
Surfactant helps to stabilize the alveolar gas bubbles 
and keep them from collapsing. Without some special system 
to prevent it, the lung would empty its smaller air spaces 
into larger ones and would then consist only of collapsed 
alveoli and hyperinflated alveolar ducts. This does not 
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occur in healthy lung because the surface tension of the 
alveolar lining is considerably less than that of plasma and 
i~ lower than predicted, and the surface tension of the 
alveolar lining decreases markedly as the film is 
compressed. This factor, in conjunction with elastic 
elements of the tissue, is sufficient to ensure the 
stability and prevent the collapse of small alveoli during 
expiration and lead to a stable balance between small and 
large alveoli. 
When Avery and Mead (1959) found that immature fetal 
lungs and the collapsed lungs of newborn babies dead of 
respiratory distress syndrome (RDS) or hyaline membrane 
disease (HMD) contained no surfactant, this material became 
a substance of great medical as well as physiologic 
importance. As a result, many investigators have now 
studied the chemical and biological characteristics of 
pulmonary surfactant. 
Composition of Surfactant 
Pulmonary surfactant was originally thought to be only 
a saturated lecithin, dipalmitoyl phosphatidylcholine. It 
is now known to be a complex lipoprotein, like those in 
membranes but unique in i.ts high concentration of 
dipalmitoyl phosphatidylcholine and its protein. 
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Glycerophospholipid 
Approximately 80-85% by weight of surfactant is 
glycerophospholipid (Mendelson et al. 1986); the major 
glycerophospholipids of surfactant are disaturated 
phosphatidylcholines (DSPC). Of the known components, the 
saturated phosphatidylcholines give the lowest values of 
surface tension and the most stable films on compression. 
This accounts for the property unique to lung extracts of 
lowering surface tension of compressed films almost to zero. 
It is thought that dipalmitoyl phosphatidylcholine 
functions as the principle molecular component of the 
surface active material in the pulmonary alveoli and that it 
bears the brunt of setting up closely-packed, stable surface 
films which can withstand high compression, and in this way 
give low values for surface tension in the alveoli. Because 
it has unsuitable physical properties for adsorption, it 
would be an ineffective surfactant if secreted in pure form. 
Clements and co-workers (Ville 1973) think that it is 
complexed with other materials such as apoprotein, 
unsaturated phospholipids and neutral lipids which enable it 
to form a film rapidly. 
Synthesis of DSPC is directly dependent upon a supply 
of palmitate from either fetal circulation or from de nova 
pulmonary synthesis. Patterson and co-workers (1986) 
investigated how de nova fatty acid synthesis is controlled 
during the critical time of surfactant production and how 
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certain lipogenic processes are related by determining 
specific short- and long-term effects of key substrates 
(lactate and glucose) and hormones (dexamethasone, insulin, 
glucagon and experimental cAMP) on fatty acid and surfactant 
lipid synthesis in fetal lung. 
Results provided evidence that metabolic regulation of 
fatty acid synthesis in lung is different from other 
lipogenic tissues and that surfactant lipid production is 
linked to fatty acid synthesis. The most likely explanation 
of this relationship is that many hormonal effects on DSPC 
synthesis may occur via a primary effect on fatty acid 
synthesis which serves as an important regulator of 
surfactant production. 
The phosphatidylglycerol in surfactant has received 
much recent attention. This phospholipid is in relatively 
low concentration in surfactant compared with the 
phosphatidylcholines, but is high when compared with other 
mammalian tissues (King 1982). Its fatty acid composition 
varies with species. It is highly enriched in saturated 
fatty acids in rat lamellar bodies and lavage fluid but 
contains mostly unsaturated fatty acids in these same 
fractions isolated from rabbit lung. 
Phosphatidylglycerol appears in fetal lung fluids at 
about the same time as there occurs a surge in the content 
of saturated phosphatidylcholine (Hallman and Gluck 1977). 
When phosphatidylglycerol is present with other surfactant 
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lipids, in the presence of calcium, these lipids interact 
with the major protein in surfactant to form a large 
molecular weight complex. This lipid-protein comple:: more 
readily adsorbs and spreads at an air-liquid interface than 
do the lipids themselves. 
Protein 
Approximately 5-10% of surfactant is protein (Mendelson 
et al. 1986). Several proteins are found in surfactant 
derived from alveolar lavage fluid. The protein most 
extensively studied has a molecular weight of 3.5-4.0 x 10 
to the fourth power, when measured under conditions that 
reduce sulfhydryl bonds (King 1974) and is probably 
specifically associated with surfactant (Clements and King 
1976). It is likely that only alveolar epithelial type II 
cells synthesize this protein, and its presence in alveolar 
macrophages derives from phagocytic ingestion. A smaller 
protein (or proteins) of about 10 to the fourth power in 
molecular weight is also present in alveolar surfactant. 
The functions of the apoproteins of surfactant remain 
uncertain. The proteins may be enzymes involved in 
glycerophospholipid synthesis and/or degradation. The 
proteins may also serve a structural role in the packaging 
of surfactant glycerophospholipid within the type II cell 
and/or in the formation of tubular myelin, an inactive form 
of surfactant, within the alveolar lumen. It has also been 
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suggested that the proteins may alter the physiochemical 
properties of surfactant by enhancing the rate of diffusion 
of surfactant glycerophospholipids over the alveolar surface 
(Mendelson et al. 1986). 
Cholesterol 
Intraalveolar cholesterol, another component of 
surfactant, may also be worth examining considering reports 
emphasizing the importance of cholesterol in normal 
surfactant production (Crittenden and Beckman 1984). 
Cholesterol may facilitate DSPC surface adsorption by aiding 
surface reentry and dispersion of DSPC molecules over the 
aqueous subphase. King (1974) found that cholesterol and 
the monoenoic phosphatidylcholines give surface active 
material increased molecular mobility and influence its 
rate of adsorption to the alveolar interface. Cholesterol 
may also enhance the rate and magnitude of rapid, reversible 
surface area changes of the DSPC film as it alternates 
between expanded and compressed states at low and high 
surface pressures. These properties of cholesterol could 
possibly influence lung function and might be reflected in 
measurements of compliance. 
A recent study was done by Crittenden and Beckman 
(1984) who wished to investigate adrenergic neural 
mechanisms involved in the release and removal of 
cholesterol and DSPC by using alpha and beta adrenergic 
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blocking drugs in combination with stellate ganglion 
stimulation. Their results provided new evidence that 
cholesterol secretion into alveolar spaces is influenced by 
beta adrenergic pathways. Furthermore, their finding of 
increased DSPC in vivo with direct neural stimulation is 
consistent with previous data from pharmacologic studies 
implicating beta adrenergic mediation of DSPC secretion. It 
would appear that adrenergic neural activity is an important 
mediator in the maintenance of a normal cholesterol/DSPC 
ratio which in turn may affect lung surface properties and 
function. 
Factors Affecting Surfactant Release 
Sympathetic Nerve Stimulation 
Biochemical analysis of lung lavage indicates that 
various forms of sympathetic activation can influence 
release of surface active phosphatidylcholine into the 
alveolar airspace. These factors include exercise (Notter 
et al. 1982), hyperventilation (Kobayashi et al. 1978), beta 
adrenergic agonists (Dobbs and Mason 1979) and stellate 
ganglion stimulation (Crittenden and Beckman 1984). While 
etiology and basic mechanisms of adult and infant RDS are 
unclear, the sympathetic nervous system appears to be an 
important influence on both (Beckman et al. 1971; Marino and 
Rooney 1981). 
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Sympathetic stimulation has been shown to play a major 
role in the development of acute pulmonary injury associated 
with mechanical central nervous system damage, surgical 
trauma, and severe non-specific stress (Ducker 1968). 
Similar findings in animals exposed to stellate ganglion 
stimulation suggest that, in addition to possible 
hemodynamic changes, the sympathetics may alter the alveolar 
surfactants prior to the subsequent development of pulmonary 
congestion and edema (Beckman and Mason 1973). 
Experiments were carried out in a study by Droste and 
Beckman (1974) to determine what effect prolonged continuous 
sympathetic nerve stimulation in cats might have on lung 
compliance and lung weight/body weight ratios. Their 
results indicated that a three hour continuous electrical 
stimulation of the stellate ganglion decreased lung 
compliance by 38% in the absence of any increase in lung 
weight/body weight ratio or lung wet weight/dry weight 
ratio. Such evidence suggests that this sympathetic-induced 
compliance decrease was due to factors other than 
cardiovascular. 
Another study addressing the effects of stellate 
ganglion stimulation was done by Crittenden and Beckman 
(1980) to determine diameters of alveolar ducts in 
spontaneously breathing cats under ketamine anesthesia. 
Examination of the outer two millimeters of the lungs by 
light microscopy revealed no alveolar duct constriction by 
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stellate ganglion stimulation, although compliance was 
decreased by 15%. Pulmonary resistance was unchanged. 
Absence of alveolar duct constriction suggests that 
peripheral airway constriction did not contribute to the 
decrease in compliance during stellate ganglion stimulation. 
A more recent study was done by Crittenden and Beckman 
(1984) in order to differentiate between airway smooth 
muscle (dynamic) effects and tissue elastic recoil (static) 
effects in producing the compliance decrease in stellate 
ganglion stimulation. Pressure-volume relationships were 
measured in situ in cats. The results of this study showed 
that stellate ganglion stimulation in cats reduced static 
lung compliance only at high lung volumes. Since stellate 
ganglion stimulation may differentially accelerate removal 
of cholesterol, and possibly protein and other adsorption-
active components, it may thereby inhibit the return of DSPC 
molecules to the air-liquid interface as the lung expands. 
Under these conditions surface tension would increase and 
compliance decrease in several breaths, as found in this 
study. 
Stimulation of the sympathetic nerves in isolated 
perfused lungs leads to an increase in pulmonary vascular 
resistance and a decrease . in pulmonary vascular compliance 
(Ingram et al. 1968). The pulmonary vasoconstriction 
during sympathetic nerve stimulation and norepinephrine 
infusion is most prominent on the arterial side of the 
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vascular bed . In addition to these pulmonary hemodynamic 
effects , sympathetic nerve stimulation decreases airway 
resistance and plays a role in surfactant turnover (Beckman 
et al . 1974) . 
It is not as well understood what the effects of 
sympathetic stimulation on lung fluid exchange may be. 
There may be alterations in transvascular fluid filtration 
secondary to pulmonary vasoconstriction, and the associated 
change in the microvascular hydrostatic pressure. A 
pulmonary edema that is rich in protein has been produced 
with large doses of epinephrine, suggesting a role for 
catecholamines in increasing the lung vascular permeability 
to proteins (Theodore and Robin 1976). 
Because of the circumstantial evidence suggesting a 
role of sympathetic mechanisms in lung transvascular fluid 
and protein fluxes, Hakim and co-workers (1979) undertook a 
study to examine the effects of sympathetic nerve 
stimulation on fluid and protein exchange in intact sheep 
lungs. They found that stellate ganglion stimulation 
resulted in increases in lung lymph flow rate, lymph protein 
flux, and protein clearance that were dependent on the 
stimulus strength, whereas the lymph-to-plasma protein 
concentration ratios remained unchanged. 
The finding that the alpha adrenergic blocking agent 
phentolamine blunted the increases in lung lymph flow, lymph 
protein clearance and protein flux during sympathetic 
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stimulation suggests that alpha adrenergic mechanisms were 
involved in the increase in lung vascular permeability. The 
finding that continuous sympathetic nerve stimulation 
resulted in increased protein transport across pulmonary 
microvessels is consistent with the observation that 
intracranial hypertension leads to increased permeability in 
sheep (Malik et al. 1979). 
In conclusion, the sustained sympathetic nerve 
stimulation as produced by stimulating the stellate ganglion 
resulted in increases in lung lymph flow and in the net 
protein flux and clearance across pulmonary microvessels. 
The results suggest a sympathetic-mediated increase in lung 
vascular permeability to proteins, and that alpha adrenergic 
activation plays a role in mediating the increase in lung 
vascular permeability. 
The mechanisms of responses of sympathetic nerves to 
hypoxia and hypercapnia and to other respiratory stimuli are 
not well understood. The role of chemoreceptors in the 
regulation of cervical preganglionic sympathetic nerve (PSN) 
activity was studied by Matsumoto and co-workers (1987) in 
anesthetized and spontaneously breathing cats. The study 
was undertaken to fill the gaps in current knowledge 
regarding PSN responses to respiratory stimuli and their 
relationship with carotid chemoreflexes. 
It was found that transection of carotid sinus nerves 
did not eliminate the PSN responses to transient changes in 
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and steady-state levels of hypoxia and hypercapnia, although 
it did eliminate the responses to brief stimulation and 
inhibition of arterial chemoreceptors by pharmacologic 
agents. The physiological meaning of the observations is 
that there are tissues other than peripheral chemoreceptors 
which can generate responses of sympathetic nervous system 
to a physiological range of hypoxic stimulus and which can 
elicit sympathetic control of physiological function, such 
as organ blood flow, independent of peripheral 
chemoreceptors. 
Glucocorticoids 
Glucocorticoids are considered to serve an important 
regulatory role in the synthesis of surfactant 
glycerophospholipids by fetal lung tissue. Abundant 
evidence has been presented to demonstrate that accelerated 
lung epithelial cell maturation and precocious production of 
lamellar bodies accompany the prenatal administration of 
glucocorticoids to mammalian fetuses. Several studies 
suggest steroid hormones affect the amount of surfactant 
phospholipids in adult lung as well, though the effects have 
not been as striking or consistent as those demonstrated in 
premature lungs (Kotas and Avery 1971; Liggins 1969; Wang et 
al. 1971). 
A recent study was undertaken by Young and Silbajoris 
(1986) to determine the effects of dexamethasone, a 
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glucocorticoid, on adult rat lung subcellular lipid 
profiles. They hoped to resolve the uncertainties regarding 
the response of the adult lung surfactant system to 
glucocorticoids. They used morphometric and biochemical 
techniques to assess the steroid effects. 
The researchers concluded that glucocorticoids alter 
lamellar body and lavage lipid content in adult rat lungs. 
The lamellar body effect is likely due to an increased 
phospholipid content per lamellar body. These data are 
consistent with two earlier observations reported by the 
same researchers. In 1982, Young and Silbajoris (1982) 
found a larger lipid pool in lamellar body fractions after 
oxygen-induced stress in rats that could be accounted for by 
morphometric estimates, and suggested that lamellar body 
composition could have been altered during the oxidant 
stress. More recently (1985), they had found that the 
stress of surgical implantation of osmotic minipumps 
increased the lavage lipid pool, an effect independent of 
beta agonists and antagonists. 
Sosenko and co-workers (1986) undertook a recent study 
to determine whether the antioxidant enzymes, like 
surfactant, might be regulated in part by an endogenous 
glucocorticoid mechanisme Metyrapone was injected into 
pregnant rats three days before delivery. Metyrapone is an 
adrenal 11-beta hydroxylase inhibitor which crosses the 
placenta and blocks endogenous glucocorticoid synthesis. 
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Significant decreases in lung tissue DSPC and 
DSPC/total phospholipids were demonstrated during the final 
two days of gestation following maternal metyrapone 
treatment. These results are in agreement with earlier 
studies with this agent showing altered surfactant levels or 
function in rabbits (Vidyasgar and Cherwick 1975), baboons 
(Kling and Kotas 1975) and guinea pigs (Nelson et al. 1976). 
This study has demonstrated for the first time a parallel 
delay following metyrapone in a nonsurfactant-related 
biochemical system in fetal lung, the antioxidant enzyme 
system. 
The maturational pattern of the antioxidant system and 
the surfactant system in fetal lung is remarkably simi~ar. 
The biochemical results suggest that human infants with 
delayed surfactant development which may be related at least 
in part to low glucocorticoid levels, may have delayed 
development of their antioxidant system as well, and may 
demonstrate intolerance to high oxygen in addition to 
hyaline membrane disease if delivered too prematurely. 
Adrenergic Effects 
The regulation and secretion of surfactant has been 
shown to be affected by beta adrenergic agonists (Brown and 
Longmore 1981; Oyarzun and Clements 1978) probably acting 
through cAMP (Mason and Dobbs 1980). Although there are 
some reports that cholinergic agonists may modulate the 
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secretion of surfactant, they are probably eliciting the 
beta adrenergic system. The parameters of ventilation 
influence the turnover of alveolar surfactant (Oyarzun and 
Clements 1977), suggesting that the amount of extracellular 
surfactant is controlled in response to changes in 
respiratory activity. Prostaglandins may also affect 
surfactant metabolism (Oyarzun and Clements 1978) but the 
contribution of prostaglandins to the overall regulation is 
unknown. Crittenden and Beckman (1984) have shown that beta 
adrenergic pathways influence cholesterol secretion into 
alveolar spaces. 
The adrenergic axis has been implicated in both 
surfactant and lung water regulation. Although there is 
considerable evidence regarding the effect of exogenously 
administered sympathomimetics on both surfactant production 
and release and lung water clearance, the role of endogenous 
catecholamines in these processes is not well defined 
(Lawson et al. 1979). McDonald and co-workers (1986) 
examined this issue by blocking beta adrenergic receptors of 
the rabbit fetus in vivo with an irreversible beta blocker, 
brornacetylalphenolomethane (BrAlp). They determined the 
effect of beta blockade on phosphatidylcholine content in 
lung tissue and lavage fluid and on lung water clearance 
from alveolar spaces. 
Results demonstrated that the administration of a beta 
blocker can decrease the amount of surfactant (measured as 
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phospholipid) recoverable by lung lavage. Although there is 
a statistically significant reduction in alveolar surfactant 
after beta blockade, the degree of reduction may not be 
biologically significant at that stage of fetal maturity. 
These data indicate that endogenous catecholamines play a 
role in surfactant secretion in both the fetal and newborn 
rabbit. No effects of BrAlp treatment on lung water were 
found, suggesting perhaps a less important role of 
endogenous catecholamines or that few receptors are required 
for this response than remained after treatment. It is 
likely that the adrenergic system is just one of several 
interacting systems that influence surfactant production and 
release at the time of birth. 
Chlorphentermine 
Another drug used in experimental studies is 
chlorphentermine. It is an anorexic agent, and one of a 
group of cationic amphiphilic drugs which produces a 
phospholipid storage disorder in the lungs of laboratory 
animals. The most striking changes in the lungs are an 
increase in the number of alveolar macrophages and 
particulate debris in the alveoli. Although the basic 
mechanism(s) responsible for the drug-induced 
phospholipidosis remains unknown, there is some evidence to 
indicate that phospholipid degradation is impaired (Miles et 
al. 19 8 6) . 
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Surfactant Removal and Reuptake 
Little is known of chemical or physical factors that 
inactivate surfactant or remove it once it is spread on the 
alveolar surface. Some may reenter alveolar cells and be 
recycled; some may enter the "liquid veins" between alveoli 
and pass into lymphatics; some may be engulfed by alveolar 
macrophages. Some have postulated that cigarette smoking 
increases the number of alveolar macrophages and so 
increases the rate of surfactant removal (Comroe 1974). 
The reuptake of surfactant phospholipids by the 
epithelium has been demonstrated in vivo by disappearance of 
phospholipid liposomes instilled into the airways (Jacobs et 
al. 1984; Oyarzun et al. 1980) and in vitro through 
accumulation of exogenous phospholipids in lung slices and 
isolated type II cells (Claypool et al. 1984). Some 
researchers demonstrated that increased ventilation results 
in an increased rate of clearance of phospholipids from the 
alveolar space, suggesting that reuptake may be 
physiologically regulated. Furthermore, since 
hyperventilation also increases surfactant secretion, 
reuptake may be linked with secretion in order to regulate 
the extracellular concentration of this material. Beta 
adrenergic mediators also stimulate surfactant phospholipid 
secretion (Massaro et al. 1982), but their affect on 
22 
clearance of phospholipids from the alveolar space has not 
been evaluated. 
In a recent study, Fisher and co-workers (1985) used 
the isolated perfused rat lung for determination of 
phospholipid clearance from the airspaces and then evaluated 
the effects of beta adrenergic agonists on this process. 
The results suggest that the retention of exogenous 
phospholipid by the isolated perfused rat lung represents 
phospholipid uptake and that the process is under beta 
adrenergic control. They concluded that secretion and 
uptake may be physiologically linked to regulate the 
concentration of surfactant on the alveolar surface. 
There is also evidence that the lung can be depleted of 
surfactant when lung volume is decreased or very large 
(Comroe 1974). When the lung is deliberately ventilated 
with low tidal volumes beginning near residual volume, it 
tends to become atelectatic and needs a new surface film 
with each inspiration. This is because a film, once 
collapsed, does not spread out again when stretched unless 
new molecules enter its surface. When a lung is 
deliberately overstretched, return to functional residual 
capacity can also promote film collapse~ 
Large tidal volumes require additional surfactant. On 
the other hand, the process of film collapse occurs much 
more slowly in static lungs than in lungs tidally 
ventilated. Since lung collapse, overdistention and large 
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tidal volumes appear to increase the requirement for new 
surfactant, it appears that, when slight differences are 
critical, the best way to maintain balance between loss and 
gain of surfactant molecules is to maintain a relatively 
high transpulmonary pressure and permit normal tidal volumes 
on this basis. This is the rationale for treating babies 
with RDS with continuous positive airway pressure. This new 
therapy has strikingly reduced mortality in babies born with 
this disorder. 
Infant and Adult Respiratory Distress Syndrome 
In 1959, Avery and Mead (1959) reported that extracts 
of lungs from infants who died from RDS were deficient in 
surfactant, that is, they had abnormal surface tension-
lowering characteristics as compared with extracts from 
lungs of newborns who had died of nonpulmonary causes. Much 
has been learned since then about the etiology, 
pathophysiology and treatment of this disease (Farrel 1982). 
The role of surfactant abnormalities in adult RDS 
is not known. Because of the heterogeneity of causes, it is 
difficult to infer a common pathogenetic mechanism in the 
development of this syndrome (Haagsman and Van Golde 1985). 
There is some evidence, however, to suggest that surfactant 
lipids are deficient or altered in patients with adult RDS 
(Hallman et al. 1982). The role of altered breathing 
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patterns and fever, if present, must also be evaluated 
(Massaro 1981; Massaro et al. 1981). 
There are many similarities between adult RDS and the 
RDS of premature newborn infants, including increased liquid 
content of the lungs with a normal pulmonary capillary wedge 
pressure (noncardiogenic pulmonary edema), alveolar 
collapse, ventilation-perfusion imbalance, right to left 
shunting of blood, decreased compliance and the development 
of hyaline membranes. Therefore, some investigators have 
suggested that adult RDS might result from defective 
surfactant synthesis (Petty and Ashbaugh 1971). 
The extent to which surfactant is compromised in other 
pulmonary diseases such as alveolar proteinosis, oxygen 
toxicity, and perhaps others, is still speculative. The 
recent findings suggesting that metabolic changes may occur 
in the surfactant system in adult RDS provide impetus to 
explore this question in other diseases (King 1982). 
Clearly, more work needs to be done before the mechanisms 
of atelectasis and reduced lung compliance present in 
patients with adult RDS are elucidated. 
Fatty Acid Composition 
Shelley and co-workers (1979) reported that surfactant 
from premature infants with HMD shows a pattern in 
phosphatidylcholine fatty acid composition that is 
distinctly different from that of a control group of 
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premature infants with mature lung formation. They observed 
a decreased compliment of palmitic acid (16:0), with an 
increase in oleic acid (18:1). The pattern becomes more 
normal as recovery occurs. A similar change has been 
observed during in utero lung development (Brumley et al. 
1967). Thus, fetal lung maturation is accompanied by 
qualitative, as well as the more generally recognized 
quantitative, changes in the pulmonary surfactant. 
Appearance of Phosphatidylglycerol 
and Phosphatidylinositol 
The appearance of phosphatidylglycerol in the tracheal 
wash of infants with HMD has been reported to be associated 
with clinical signs of recovery. Jackson and co-workers 
(1986) tested the hypothesis that recovery from experimental 
HMD begins only after an increase in the synthesis and 
secretion of phospholipid rich in the surfactants 
phosphatidylglycerol and DSPC. In order to examine the 
recovery process _in HMD in vivo methods not feasible in 
humans, the researchers have previously studied nonhuman 
primates with experimental HMD (Jackson et al. 1985). The 
observations that deflatiort stability improved over the 
first 12 hours of life even though total lung capacity 
declined and remained low for the first two days caused the 
researchers to investigate the timing and role of surfactant 
synthesis and secretion in the recovery process. 
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Compared to 140-day fetuses, the healthy controls had a 
several-fold increase in lavage phospholipid and DSPC during 
the first few days of life. Prior to recovery, animals with 
HMD had no such increase in lavage phospholipid or DSPC and 
demonstrated poor deflation stability. Recovery was 
associated with increased tissue and lavage phospholipid and 
increased fractions of phosphatidylinositol and DSPC but not 
phosphatidylglycerol. The tissue compositional changes 
observed during recovery reflected maturational changes 
observed in the fetal animals studied at ten days greater 
gestational age. The authors conclude that increases in 
DSPC and phosphatidylinositol are associated with recovery 
from HMD but phosphatidylglycerol does not appear necessary 
for either improved deflation stability or clinical 
recovery. 
A similar finding with regard to phosphatidylglycerol 
was found by Liau and co-workers (1985). In a study of 
isolated lungs from bronchioalveolar lavage of dogs, they 
found that phosphatidylglycerol may not be a critical 
determinant of lung surfactant function and that its 
specific role in the surfactant may be assumed by 
phosphatidylinositol. 
Surfactant Inhibitory Activity 
RDS, besides being characterized by volume loss and 
decreased compliance, is also associated with pulmonary 
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edema, bronchiolar epithelium destruction, and a leak of 
plasma proteins into the airways and alveoli (Jobe et al. 
1983; Nilsson et al. 1978; Said et al. 1965). The alveolar 
pulmonary edema may inactivate surfactant in vivo since 
plasma proteins can inhibit surfactant function in vitro 
(Jobe et al. 1983). 
To further characterize the effect of surfactant 
inhibition by proteinaceous pulmonary edema, Berry and co-
workers (1986) used the model of bilateral cervical vagotomy 
in adult rabbits. Respiratory distress in the vagotomy 
rabbits was characterized by a marked decrease in lung 
compliance, an increase in alveolar-arterial oxygen 
gradient and atelectasis and results at least in part from 
surfactant dysfunction caused by the proteinaceous pulmonary 
edema. This phenomenon of surfactant inhibition by plasma 
proteins is consistent with findings in RDS and supports the 
authors' belief that inhibitory activity plays an important 
role in this disease. This disruption of surfactant 
function can be partially overcome by a treatment with 
natural surfactant. 
Another study addressing surfactant inhibitory activity 
was carried out by Ikegami and co-workers (1986). They 
wondered whether a protein inhibitor could be isolated from 
cord blood, amniotic fluid and airway samples from infants 
with RDS and whether the quantity of airway-associated 
inhibitor might correlate with disease severity. This 
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inhibitor presumably appears in the alveoli because of the 
abnormal protein leak present in the lungs of infants with 
RDS. 
Inhibitor protein was found in serum and amniotic fluid 
of both infants with RDS and normal infants. The 
researchers presumed the inhibitor protein is a normal serum 
component that can incidentally disrupt surfactant surface 
properties when it enters the alveoli. Their results are 
consistent with the concept that the inhibitor contributes 
to surfactant dysfunction and thus the respiratory failure 
characteristic of RDS. 
Rice and Singleton (1985) demonstrated marked 
inhibit~on of surfactant secretion from isolated type II 
cells by the polyamines. Since inhibition of surfactant 
secretion appears to be mediated by small polybasic 
compounds, Rice and Singleton (1986) undertook a study to 
test the hypothesis that substance P regulates surfactant 
secretion in isolated type II cells. 
Substance Pis an undecapeptide. This neuropeptide is 
distributed throughout the central and peripheral nervous 
system as well as the gastrointestinal tract, and has also 
been recently identified in lung tissues (Barnes 1984; 
Lazarus et al. 1983). The function of these neuropeptides 
in lung is unclear at the present time. 
The results of the present study demonstrate inhibition 
of [3H] phosphatidylcholine secretion by substance P. This 
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supports the hypothesis that amino-terminal basic groups of 
substance Pare necessary for inhibition of surfactant 
secretion from isolated type II cells and support the 
concept that an inhibitory system contributes to mediation 
of surfactant secretion from type II epithelial cells. 
Surfactant Replacement 
Substitution Therapy 
Many advances have been made in the care of newborn 
infants with RDS. Nevertheless, this disease remains an 
important cause of mortality and morbidity in the low birth 
weight infant. Surfactant substitution is a promising way 
to treat or prevent RDS (Enhorning and Robertson 1972; 
Fujiwara et al. 1980) and would be of benefit in these 
infants. 
Surfactant TA 
Early attempts to replace surfactant in infants with 
RDS were unsuccessful due to incomplete knowledge of 
surfactant composition and improper delivery methods (Gitlin 
et al. 1984). Recently Fujiwara and co-workers (1980) have 
treated newborn infants with RDS using a well-characterized 
organic solvent extract of beef lung surfactant (surfactant 
TA). A dramatic decrease in the oxygen requirement was 
demonstrated in these infants within three hours after 
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treatment. Promising results have also been shown by 
Enhorning and co-workers (1985) using a bovine surfactant 
and by Hallman and co-workers (1985) using huQan surfactant 
isolated from term amniotic fluid. 
In a more recent study, Hallman and co-workers (1986) 
attempted to analyze the quality, quantity and turnover of 
surfactant phospholipids among the small preterm infants who 
received natural homologous surfactant in a randomized trial 
to treat severe RDS. The control infants tended to have 
lower saturated phosphatidylcholine/sphingomyelin ratios 
during the first week than the surfactant-treated infants. 
The recipients of surfactant had slightly more serious lung 
disease than the controls when the results were adjusted by 
covariance to remove the differences in the saturated 
phosphatidylcholine/sphingomyelin ratio. Exogenous 
surfactant increased the apparent endogenous pool size at 
least five-fold. The half life was independent of the 
amount of exogenous surfactant. Clearly, the present and 
previous data (Jobe et al. 1983; Stewart-DeHann et al. 1980) 
. contradict the possibility that exogenous surfactant in RDS 
inhibits endogenous synthesis and secretion. 
Gitlin and co-workers (1987) undertook a study most 
recently to critically assess the role of surfactant 
replacement in the treatment of HMD. They used a well-
characterized bovine surfactant preparation (surfactant TA) 
that has the potential of becoming widely available and is 
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free of human pathogens (Fujiwara et al. 1979; 1980). The 
findings from this study demonstrate that surfactant TA 
given early in the course of severe HMD leads to a prompt 
and sustained improvement in oxygenation and a decrease in 
the need for ventilatory support. Surfactant TA may offer 
an advantage over human and other currently available 
exogenous surfactants in its potential for wide 
availability, quality control, and demonstrated efficacy. 
Nevertheless, long-term studies will be needed to ensure the 
safety of TA surfactant, especially in view of potential 
immunologic effects from bovine-derived material. 
A recent study by Ikegami and co-workers (1987) 
compared natural sheep surfactant, rabbit surfactant, human 
surfactant and surfactant TA for in vitro surface properties 
and for responses of preterm lambs to treatment. Although 
all surfactants were superior to no treatment in these very 
preterm surfactant-deficient lambs, surfactant TA, the 
surfactant with the best in vitro properties based on 
standard criteria, was not the best surfactant when tested 
in vivo in the premature lamb. 
The authors suggested that in vitro surface properties 
as presently used to develop surfactants for clinical use 
will not accurately predict in vivo responses because of 
present poorly understood interactions of different 
surfactants with the preterm lung. Once several surfactants 
are available for clinical use, they will need to be 
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directly compared in clinical trials to establish which 
preparation is the most effective. 
Animal or human surfactant extracts placed into the 
trachea at birth or when respiratory failure develops have 
been shown to improve the oxygenation of premature babies 
and thus reduce the incidence of severe complications. In a 
University of Illinois study (1987), 30 neonates with birth 
weights of 751 to 1750 grams and severe hyaline membrane 
disease received a single dose of reconstituted bovine 
surfactant within six hours of birth. Three of the 17 
babies treated died, compared with seven of 13 who received 
placebo, Pneumothorax and pulmonary interstitial emphysema 
were more common in the placebo group, while hemodynamically 
significant patent ductus arteriosis (PDA) was seen more 
frequently in the treated babies. The authors note that 
because five placebo deaths occurred sooner than the age at 
which clinical signs of PDA are usually manifest, the PDA 
incidence was undercounted in the placebo group. 
Although in animal subjects better results were 
obtained when surfactant was instilled at birth, the authors 
recommend that use of bovine surfactant be restricted to 
infants with established lung disease or lung immaturity. 
As they point out, not all premature or low-birth-weight 
infants will develop hyaline membrane disease. 
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Current Research Rationale 
Other investigators have used ultrastructural methods 
to evaluate the secretory response of alveolar type II cells 
to exogenous catecholamines (Massaro and Massaro 1983; Smith 
et al. 1982) . Among other advantages, this approach allows 
direct examination of the type II cell. Increased 
surfactant in lung lavage from sympathetic nerve stimulated 
cats has provided additional support for a direct neural 
influence on type II cells. 
Cats will be used in this research because in this 
species the stellate ganglion is easy to find 
retropleurally. The retropleural approach is crucial due to 
the necessity of keeping the chest and pleural space intact 
to preserve functional integrity as closely as possible. 
Other small laboratory species are unsuitable due to lack of 
stellate ganglion. 
The cat also has the largest stellate ganglion of any 
species, comprising the fused inferior cervical ganglion and 
the first four thoracic ganglia. Thus the cat is a more 
appropriate model for studying sympathetic effects of 
stellate ganglion stimulation on the lung, because the third 
and fourth ganglia supply the pulmonary plexus (Crouch 
1969). 
The diseases of infant and adult RDS have been rather 
resistant to improvement and care (Bone 1984), and it is now 
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apparant that merely supplying replacement surfactant 
components to the lungs' airway does not always restore lung 
compliance. With a few notable exceptions (Jobe 1986; 
Tanaka et al. 1986) surfactant replacement therapy does not 
appear to have widespread clinical usage. The solution to 
the problem, therefore, is to be found by understanding 
basic mechanisms of these surfactant deficiency syndromes. 
One of those basic mechanisms involves understanding the 
type II cells that secrete surfactant (Freiherr 1985). The 
present research addresses this problem and it is hoped that 
the results, taken with information from other researchers 
studying basic mechanisms of surfactant release and 
activation, will ultimately reduce the 50% mortality rate of 
RDS sufferers (Andreadis and Petty 1985). 
The studies mentioned indicate conflicting evidence 
regarding surfactant metabolism, therefore, the present 
study was undertaken in order to further define the role of 
the sympathetic nervous system in surfactant release. 
Ultimately, knowledge regarding surfactant release and 
activation will be immensely important to health care 
personnel dealing with infant and adult RDS. 
METHODS AND MATERIALS 
Animals 
Tissue for this thesis research was obtained from 
experimental cats. These cats were previously treated with 
stellate ganglion stimulation as described below. 
Sixteen cats (Pearcroft Farms, Beaufort, NC) 
anesthetized with ketamine (Ketalar, Parke-Davis, Atlanta, 
GA) were ventilated in the supine position for 30 minutes 
with 100% oxygen via tracheal cannula. The right stellate 
ganglion of four control and four experimental cats was 
exposed retropleurally via an incision through the skin and 
muscle layers under the scapula. In control cats the 
ganglion was not manipulated any further. In stellate 
stimulated cats an electrode was placed on the ganglion in 
order to provide an electrical stimulus. 
After an appropriate time interval, each cat was 
disconnected from the ventilator and the chest opened with a 
midline incision. The lungs were allowed to collapse for 60 
seconds to ensure complete degassing. Fixative (modified 
Karnovsky's) perfused the vasculature at a pressure of 20 
centimeters water via an incision in the right ventricle 
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(Callas 1974). The left atrium was cut to allow escape of 
the pulmonary perfusate. At the same time, fixative was 
infused into the lungs via the tracheal cannula at a 
pressure of 20 centimeters water. The perfusion was 
continued for 30 minutes. After 30 minutes one cubic 
millimeter blocks of lung tissue were removed from the 
middle right lobe and put into cold fixative identical to 
the perfusate for an additional two hours. Tissue cubes 
were then post fixed in one percent osmium tetroxide in 
0.1 M phosphate buffer for an additional two hours, 
dehydrated in a series of ethanol and propylene oxide, and 
embedded in Polybed 812 embedding plastic (Polysciences, 
PA). 
Thin (60-80 nanometer) sections were obtained from 
embedded tissue blocks using a Reichart OM-2 ultramicrotome. 
Sections were stained with uranyl acetate and lead citrate 
and examined in a Hitachi HS8-2 transmission electron 
microscope. Ultrastructural features were observed and 
micrographs were taken of type II cells which exhibited 
microvilli and cuboidal epithelium. 
Sympathetic Stimulation Principles 
In order to produce neurally mediated sympathetic 
activation of parenchymal lung tissue, in four cats the 
exposed stellate ganglion was stimulated with a wire 
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electrode connected to a Grass S-44 stimulator (Hato Rey, 
Puerto Rico). The electrode delivered seven volts at a 
frequency of ten pulses per second and duration of ten 
milliseconds. These parameters have been determined to be 
least likely to produce stiffening of pulmonary vessels 
(Ingram et al. 1968) while providing sympathetic activation 
of the parenchyma. The stellate ganglion was stimulated for 
six minutes. This time interval seemed to provide the 
greatest visualization of ultrastructural changes from SGS. 
Morphologic Analysis 
In order to analyze morphological changes in alveolar 
type II lining cells of cats receiving stellate ganglion 
stimulation, prints developed from electron micrograph 
negatives were enlarged to 10,000 times or larger on 
8 X 10 inch photographic paper and observed. 
Electron micrographs of lung tissue from stellate 
stimulated cats were compared to micrographs of lungs of 
normal controls. Careful attention was paid to appearance 
of type II cells in lungs from control versus SGS cats. 
Specifically, lamellar inclusion bodies were of interest 
and were examined for relative numbers and disposition 
throughout the cytoplasm of the type II cell. Also 
examined were the basement membranes of epithelial and 
endothelial cells in order to confirm that these membranes 
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remained fused. In addition, mitochondria and microvilli 
of type II cells were examined. Observation was also 
made of contractile interstitial elements. The appearance 
of thin squamous type I epithelium was also observed. 
RESULTS 
Lung tissue from four sham treated control cats was 
compared to lung tissue from four stellate stimulated cats. 
Over 100 micrographs of 10,000x magnification were studied. 
Ultrastructural examination of alveolar morphology by TEM 
revealed a consistant decrease of lamellar bodies in 
alveolar type II cells of sympathetically stimulated cats. 
This is evidenced by comparison of type II cells in Figures 
1 and 2. Figure 1 illustrates the usual abundance of 
lamellar bodies in type II cytoplasm of control tissue. 
Figure 2, a micrograph of lung tissue from SGS cats, shows 
relatively fewer lamellar bodies contained within the cell 
cytoplasm. Some type II cells from SGS cats contained no 
lamellar bodies. These two micrographs are representative 
of the majority of control and SGS lung tissue, 
respectively. 
Large oval vacuolated areas occurred within the 
cytoplasm of the type II cells of both control and stellate 
tissue. These vacuoles occurred with similar frequency in 
the type II cells of control and SGS cats. Vacuoles seemed 
to be found more frequently in the basal portions of the 





Representative type II cell profile from control 
cat. Note abundance of lamellar bodies (LB) 
relative to cytoplasm volume. Note presence of 
vacuolated inclusions (V) similar in size and 
shape to lamellar bodies. Base of cell is 
indicated by arrows showing basement membrane 
(X8800) . 
Representative type II cell profile from SGS 
Cell contains relatively few lamellar bodies 
compared to Figure 1 control tissue. Note 
presence of vacuolated inclusions (V). Base 






Figure 3 shows typical lamellar inclusion bodies. The 
osmiophilic lamellae in each inclusion body were unaltered 
by SGS. Lamellar bodies did not exhibit any change in size 
with SGS. 
Numer0us mitochondria were observed and seen with equal 
frequency in control and SGS cats (Figure 4). Although 
distinct cell membranes were observed, cristae were poorly 
visualized in most cases. The interior of most mitochondria 
was homogenous and dark in appearance. 
Type II cells were easily identified by the appearance 
of microvilli (Figure 5). There were no differences noted 
between control and SGS tissue with respect to size, number 
or general appearance of microvilli. 
Figure 6 shows the thinness of the squamous type I 
epithelium and capillary endothelium. No nuclei of type I 
cells were noted in over 100 micrographs of lung tissue. 
Note the profusion of pinocytotic vesicles in capillary 
endothelium contrasted with relatively few vesicles in type 
I epithelium. 
Basement membranes showed fused basal laminae of 
alveolar epithelium and capillary endothelium (Figure 6). 
The basement membranes remained intact and fused, and were 
not affected by the stimulation. None of the micrographs 
indicated separation of the fused membranes or infiltration 
of fluid into the interstitium between membranes. 
Figure 3. Examples of lamellar inclusion bodies. Note 
abundance of osmiophilic material, or lamellae, 
in each inclusion body. This type II cell is 
from a control cat (Xl3,400). 
Figure 4. Example of mitochondria (M) in type II cell. 
Note cristae within the mitochondria. Stellate 
stimulation did not appear to alter the 
mitochondria (X7150). 

Figure 5. Example of microvilli lining characteristic of 
type II cell. The microvilli are located at the 
air-blood barrier (X8600). 
Figure 6. Representative squamous type I epithelium (Ep). 
Note absence of nuclei. Example of basement 
membrane (B) showing how basal laminae of type I 
epithelial and capillary endothelial cells are 
fused. Note that membranes show no indication of 
separation and that pinocytotic vesicles (P) are 
plentiful in the cell cytoplasm (Xll,000). 
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Macrophages were easily differentiated from alveolar 
type II cells by the fact that the macrophages were 
completely free in the alveolar airspace and shared no 
basement membrane with the alveolar wall (Figure 7). 
Macrophages occasionally contained inclusions resembling 
lamellar bodies. Long cytoplasmic processes projected from 
the peripheral cytoplasm. 
Contractile interstitial elements as described by 
Kapanci and co-workers (1976) were present in some sections 
(Figure 8). These elements are made up of collagenous 
fibrils and elastic fibers. Appearance of these elements 
did not seem to be related to SGS, as they were observed 
with equal frequency in both control and SGS cats. 
Membranes of cells containing contractile elements were not 
easily identifiable, and the cells appeared to be very 
irregular. 
The monolayer of surfactant covering alveolar surfaces 
in life was absent in all micrographs. This finding most 
likely reflects destruction of lipid by the aldehyde in the 
modified Karnovsky's solution employed in tissue fixation. 
Thus information regarding disposition of this surfactant 
layer over the alveolar surface in control versus SGS cats 
was not available. 
Glycogen granules were not observed in type II cells of 
these mature control or SGS cats in any micrographs. This 
finding is consistent with disappearance of these granules 
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with maturity (Kikkawa et al. 1968, 1971; Sorokin 1961; 
Williams and Mason 1977). 
Figure 7. 
Figure 8. 
Representative macrophage completely free in the 
alveolar space. Note cytoplasmic processes (CP) 
projecting from peripheral cytoplasm (X6700). 
Contractile interstitial elements (CE) made up of 
collagenous fibrils and elastic fibers in the 
interstitium of the alveolar region. Elements 
that appear as dots represent cross-sections of 
the contractile fibers (Xl0,750). 

DISCUSSION 
The most important data generated by this thesis 
research were the morphologic changes observed with the 
transmission electron microscope (TEM). The most 
significant event was depletion of surfactant stores from 
alveolar type II cells of SGS cats. TEM showed fewer 
lamellar bodies per type II cell of SGS cats visually 
compared to control cats. It is well established that 
depletion of secretory granules from secreting cells is 
indicative of increased secretion. 
In comparing Figures 1 and 2, it is evident that the 
control type II cell contains a greater number of lamellar 
bodies. This is consistent with biochemical data 
suggesting sympathetic control of phospholipid secretion 
(Brown · and Longmore 1981; Crittenden and Beckman 1984; 
Dobbs and Mason 1979; Mason and Dobbs 1980; Massaro et al. 
1981; Oyarzun and Clements 1977, 1978; Young and 
Silbajouris 1985). Although observations of these 
micrographs suggested depletion of intracellular 
surfactant, the process of extrusion was not observed. 
This is in contrast to frequent observations by Smith and 
co-workers (1979) of lamellar bodies in the process of 
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being secreted into the alveolar space in pilocarpine 
treated rabbit fetuses near term. Massaro and co-workers 
(1981) have correlated biochemical evidence of 
phospholipid secretion with ultrastructural documentation 
of lamellar body depletion in response to the beta agonist 
isoproterenol. 
Based on objective observation of altered lamellar 
body content from SGS, this thesis research provided 
further support for a nerve link between the sympathetic 
nervous system and alveolar type II cell surfactant 
secretion. Investigation of the role played by neural 
innervation in mediating lamellar body depletion is 
discussed in reports describing nerve endings near type II 
cells in alveolar walls of mouse lungs (Meyrick and Reid 
1971; Hung et al. 1973). These nerve endings are dense 
cored, suggestive of motor (stimulatory) function (Hung et 
al. 1973). The possibility of neural innervation of type 
II cells has been directly implicated by a study of 
surfactant release during exercise (Nicholas et al. 1982). 
Shepard and co-workers (1982) reported morphometric 
data on excised dog lungs. They evaluated the impact of 
alterations in ventilation, substrate availability, 
alveolar carbon dioxide tension, hydrogen ion and 
bicarbonate concentrations, and temperature and neural 
denervation on the lamellar body volume density of type II 
cells. Their data suggest that alveolar hypercapnia via 
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its effect in reducing bicarbonate concentration appears 
to be the major environmental factor mediating the 
depletion of lamellar bodies from type II cells. This 
process was temperature dependent and did not require the 
presence of intact neural innervation. 
It is unclear what factors control the secretion of 
pulmonary surface active material from alveolar type II 
cells. Various researchers have suggested that 
cholinergic stimuli, adrenergic stimuli and prostaglandins 
may all stimulate secretion (Mason and Dobbs 1980; Oyarzun 
and Clements 1978). Wyszogrodski and co-workers (1974) 
showed that injections of isoxsuprine to 28 day old rabbit 
fetuses three hours before delivery increased the lung 
stability of the rabbits after delivery. They felt that 
this increase in stability might be the result of an 
increase in the amount of alveolar surface active 
material. Olsen (1972) found that isoproterenol, in a 
single injection to a rat, caused a decrease in the number 
of lamellar bodies per type II "cell profile" and an 
increase in the phospholipid content in lung lavages; ~his 
effect could be blocked by propranolol. This 
ultrastructural thesis research confirms Olsen's findings 
by also showing lamellar body depletion. 
Dobbs and Mason (1979) have shown that isolated 
alveolar type II cells release DSPC in response to beta 
adrenergic stimulation. It is likely that secretion of 
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surface active material in vivo is modulated by beta 
adrenergic mechanisms acting directly on type II cells. 
Resulti obtained by Crittenden and Beckman (1984) with 
alpha blockade and SGS provide evidence that nerve 
stimulation also may increase lavage DSPC through beta 
receptors. There is thus reasonable evidence that beta 
adrenergic stimulation can increase the release of 
components of lung surfactant. 
The time course used for the release of surfactant in 
this thesis research was six minutes. This time interval 
seemed to provide the greatest assurance of visualization 
of ultrastructural changes from SGS. Dobbs and Mason 
(1979) showed a 50% increase over basal levels of DSPC 
release within 15 minutes of administration of the beta 
agonist terbutaline to isolated rat type II cells in 
culture. Oyarzun and Clements (1978) found a 43% increase 
in DSPC recovered in lung wash following administration of 
terbutaline via the pulmonary artery in rabbits. Olsen 
(1972) found increased phospholipid and depleted type II 
cell lamellar bodies in lungs of rats given isoproterenol 
30 minutes prior to sacrifice. The isolated perfused rat 
lung was used by Nicholas and co-workers (1982) to examine 
the effect of a deep breath. Following 30 minutes of 
normal ventilation, a large breath increased the amount of 
alveolar surfactant phospholipids within 30 seconds. The 
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deep breath also resulted in an increase in oxygen 
diffusing capacity. 
In their study of the effects of dexamethasone on 
surfactant, Young and Silbajouris (1986) obtained results 
from adult rats. Vidic and Burri (1981) studied 
quantita~ive changes in the rat type II cell during late 
postnatal development. Their results showed a ten-fold 
increase in volume density of lamellar bodies compared to 
those reported by Young and Silbajouris (1986). 
Lamellar body volume density reported with dogs 
(Shepard et al. 1982) exceeded numbers obtained using 
adult (Young and Silbajouris 1986) and postnatal rats 
(Vidic and Burri 1981). Although there appears to be an 
increase in morphometric data with larger animals, the 
difference between postnatal and adult type II cells, at 
least in rats, exhibits a much greater increase. 
Mitochondria at one time were considered the 
intracellular precursors of lamellar inclusion bodies 
(Klaus et al. 1962). Later researchers found that this is 
not the case partly because increased surfactant in fetal 
lungs paralleled the increase in type II lamellar bodies 
but not in mitochondria. The present thesis results are 
consistent with the view that lamellar body depletion is 
not related to mitochondrial changes, because changes in 
morphology or cytoplasmic density of mitochondria were not 
seen in lamellar body-depleted SGS lung tissue. In no 
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micrographs were there any cristae seen in lamellar 
bodies, nor were any osmiophilic lamellae seen in 
mitochondria. 
mitochondria. 
In fact, cristae were rarely seen in 
These thesis results support the now 
generally accepted conclusion that lamellar bodies are 
separate and distinct organelles from mitochondria. 
Type I epithelium exhibited no changes with SGS. No 
nuclei or glycogen were observed in the numerous 
micrographs studied. 
The integrity of the basement membranes was not 
affected indicating that SGS effects were manifested 
elsewhere in parenchymal lung tissue. Other areas 
affected may include type II cells, contractile 
interstitial elements, lung lymph flow, and possibly other 
sites. 
Macrophages observed often exhibited long cytoplasmic 
processes projecting from the peripheral cytoplasm. In 
general, nuclei were spherical in shape with some 
indentation, although more irregularly shaped nuclei were 
also seen. The presence of occasional lamellar body-like 
structures in the macrophages was most likely the result 
of phagocytosis (Clements and King 1976). Occasionally 
the content of lysosomes within macrophages reveals a 
myelin figure (Ebe and Kobayashi 1972). 
Vacuoles were present in some of the type II cells 
observed. They appeared to be about the same size and 
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shape of lamellar bodies and their locations within the 
cell were similar, but they contained no lamellae. Most 
appeared near the base of the cell. Their presence may 
indicate areas that were washed out by the series of 
alcohol dehydrations that were used in preparing the 
tissue for TEM. Kikkawa and co-workers (1986) concluded 
that these vacuolated inclusions represented areas of 
surfactant secretion. 
Contractile interstitial elements were observed 
frequently in the interstitium of the alveolar region in 
both SGS and control cats. During ordinary breathing, the 
elastic fibers do not undergo much linear extension. 
Their role is to serve as protection against shock to the 
extensible collagenous fibers if some of them should 
rupture during coughing or sneezing (Kapanci et al. 1976). 
SGS did not seem to alter the contractile elements with 
respect to frequency of appearance in control and SGS 
cats. This thesis research did not specifically examine 
the influence of sympathetic stimulation on contraction of 
interstitial elements. However, interstitial contraction 
may have had an effect on surfactant release by altering 
blood flow through pulmonary capillaries subserving 
alveolar type II cells (Kapanci et al. 1976). The 
contraction of interstitial cells might fold the alveolar-
capillary tissue barrier into the vascular space by 
pulling on the alveolar basement membrane. Interference 
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of intracapillary folds with corpuscular blood circulation 
may have influenced depletion of lamellar bodies. 
The absence of glycogen granules in type II cells of 
these mature control and SGS cats was expected. This 
thesis research did not emphasize glycogen, but it is 
interesting to note its absence with numerous reports 
suggesting disappearance of these granules as maturity 
approaches (Kikkawa et al. 1968, 1971; Sorokin 1961; 
Williams and Mason 1977). 
The absence of the monolayer of surfactant covering 
alveolar surfaces most likely reflected the destruction of 
lipid by the aldehydes in the modified Karnovsky's 
solution employed in tissue fixation. Thus, information 
regarding the disposition of this surfactant layer over 
the alveolar surface in control versus SGS cats was not 
available. This is unfortunate because some important 
functional correlates of hastened lamellar body depletion 
from SGS cats may have been deduced from these results. 
This represents an area for further study. 
This study has provided evidence of a direct nerve 
influence on release of surfactant from alveolar type II 
cells. This is the first direct evidence of depletion of 
surfactant by sympathetic nerve stimulation, extending 
earlier observations demonstrating the influence of 
circulating catecholamines on release of surfactant from 
alveolar type II cells. 
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Further study is needed to determine what presently 
unknown factors are responsible for surfactant function 
and whether or not the proper disposition of these 
components is understood well enough to permit proper 
dispersion and function of replacement surfactant in vivo. 
Further study using stellate ganglion stimulation 
differentiating between alpha and beta adrenergic pathways 
is needed to clarify specific adrenergic pathways in 
surfactant release. In addition, it remains unclear what 
the actual time course may be for tne first significant 
release of surface active material. The next step is to 
study this time course by using shorter intervals of 
stimulation, such as 30 to 60 seconds. 
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